Dayvoneks ointment 50mkg / g 30g tuba

Description

Composition
Active substance:
50.0 g calcipotriol.
Excipients:
alpha-tocopherol 20 g, macrogol stearate 50 mg propylene glycol 100 mg Disodium edetate dihydrate 65 g sodium hydrogen phosphate dihydrate, 260 .mu.g, paraffin liquid (containing about 10 ppm alpha-tocopherol) 50 mg, water 26 mg, paraffin, white soft (contains about 10 ppm alpha-tocopherol) to 1 g
Description:
translucent ointment from white to white with a yellowish tinge.
Product form:
Ointment for external use 0.005%.
30 g of the ointment in an aluminum tube, coated on the inside, with a protective membrane and a plastic screw cap having a tenon on the outer side of the first opening of the protective membrane; 1 tube together with instructions for use in a cardboard box.
Contraindications
Hypersensitivity to Calcipotriol and any excipient the formulation;
Diseases associated with impaired calcium metabolism;
Children up to age 6 years.
Be wary – hypercalcemia, hypercalciuria, vitamin D hypervitaminosis, nephrolithiasis history, age over 65 years, acute renal and hepatic failure.
Indications
Psoriasis vulgaris (including in combination with acitretin, cyclosporine or corticosteroids).
Interaction with other drugs
Dayvoneks® ointment should not be used together with drugs for topical application,
containing salicylic acid
Overdose
Use of the drug in doses exceeding recommended may cause an increase in calcium concentration in blood. In this case, treatment should be discontinued.
pharmachologic effect
Pharmacological group:
means for treating psoriasis.
Pharmacodynamics:
Calcipotriol is an analog of natural active metabolite of vitamin D3.
Stimulates morphological differentiation and suppresses proliferation of keratinocytes that lies at the heart of its therapeutic effect in psoriasis.
Calcipotriol is an inhibitor of T lymphocyte activation caused by interleukin 1.
The effect on calcium metabolism of calcipotriol is 100 times weaker than with calcitriol.
Pharmacokinetics:
Transdermal absorption of calcipotriol is from 1% to 5% of the dose.
Calcipotriol undergoes rapid biotransformation in the liver to produce pharmacologically active metabolites. The half-life is very short.
Pregnancy and breast-feeding
Safety of the drug during pregnancy and lactation has not been established. It is not known whether calcipotriol in breast milk is released. Should be avoided during pregnancy and lactation
Conditions of supply of pharmacies
Without recipe.
side effects
Data are presented in accordance with the following frequency of occurrence:
Very often> 1/10
Often> 1/100 and 1/1000, and 1/10000 and
Violations by the immune system:
Very rarely, allergic reactions, urticaria, angioneurotic edema;
Violations by the metabolism:
Very rare: hypercalcemia, hypercalciuria;
Violations of the skin and subcutaneous tissue disorders:
Common: skin irritation, rash (scaly, erythematous, maculo-papular, pustular,
bullous), burning sensation, dryness and peeling of the skin, pruritus, erythema
Not often: flow exacerbation of psoriasis, eczema, contact dermatitis;
Very rare: reversible hyperpigmentation, reversible depigmentation of reversible development of photosensitivity, periorbital or facial edema.
special instructions
Do not apply ointment Dayvoneks® face. In order to avoid contact with skin faces hands should be washed thoroughly after each application of ointment.
Appointment of patients younger than 18 years can only be short courses and on the skin surface, not exceeding 30% of the body surface.
Should not be applied to large surfaces lesions (more than 30% of the skin surface).
Not recommended for large skin surfaces or severe chronic psoriasis (due to increased absorption intensity and increase the risk of hypercalcemia). If it becomes necessary to use in these forms of psoriasis, it requires careful monitoring of the concentration of calcium in the blood and urine.
Hypercalcemia may occur when exceeding a maximum weekly dose of calcipotriol. To remove the drug in the blood calcium concentration rapidly returning to normal.
In the case of an ointment, together with a solution should take into account that the total dose of calcipotriol should not exceed 5 mg per week (1 mL Dayvoneks® solution scalp Dayvoneks® corresponds to 1 g of ointment).
During treatment Dayvoneks® doctors recommend patients to limit or avoid excessive exposure to either natural or artificial sunlight. Treatment can be combined with a selective and PUVA – phototherapy, as well as with treatment with UV – light, if the doctor believes that the potential benefit outweighs the potential risk.
Effects on ability to drive and moving machinery
Calcipotriol does not affect the ability to drive vehicles, machinery.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children
Once opened, store the drug 6 months.
Dosing and Administration
Outwardly.
Adults
Ointment applied a thin layer to the affected areas of the skin 2 times per day. If necessary, the frequency of use of the drug can be reduced to 1 times a day.
The combined use of ointment acitretin or cyclosporin 2 times a day effective and well tolerated.
Combined application of ointments with corticosteroids is performed according to the scheme
for example, an ointment – in the morning, a corticosteroid – in the evening.
The maximum daily dose should not exceed 15 g, and a maximum weekly dose of not more than 100 g
The therapeutic effect is usually observed within 1-2 weeks of starting treatment.
The duration of treatment no more than 6-8 weeks.
Children
At the age of 12 years: Apply a thin layer of ointment to the affected skin 2 times a day, the maximum dose per week should not exceed ’75
At the age of 6 to 12 years: a thin layer of ointment applied to the affected skin 2 times per day. The maximum dose for a week no more than ’50
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist